Free Trial
NASDAQ:BOLT

Bolt Biotherapeutics Q4 2024 Earnings Report

Bolt Biotherapeutics logo
$0.37 -0.02 (-5.08%)
Closing price 04/28/2025 03:59 PM Eastern
Extended Trading
$0.38 +0.01 (+1.84%)
As of 04/28/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bolt Biotherapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.38
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bolt Biotherapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.79 million
Beat/Miss
Missed by -$780.00 thousand
YoY Revenue Growth
N/A

Bolt Biotherapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 24, 2025
Conference Call Time
5:00PM ET

Upcoming Earnings

Bolt Biotherapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Bolt Biotherapeutics Earnings Headlines

Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Bolt Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email.

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

View Bolt Biotherapeutics Profile

More Earnings Resources from MarketBeat